Someone reads that BPC-157 may be added to the 503A bulks list and asks a fair question: what list, and what would change? The short answer is that Section 503A lets a licensed pharmacist prepare a medication for one identified patient from a prescription. The bulks list is the narrow route for a raw active ingredient that has no applicable USP or National Formulary monograph and is not a component of an approved drug. It is a pharmacy-compounding rule, not a finding that the ingredient works.
This is the long-form version of a Promise analysis distributed September 8, 2026 via FinanceWire and carried by Markets Insider.
The 503A bulks list is an ingredient rule
Section 503A entered the Federal Food, Drug, and Cosmetic Act in 1997 and was revised when Congress enacted the Drug Quality and Security Act in 2013. In broad terms, it creates conditions under which traditional pharmacies can compound a drug for an individual patient based on a valid prescription. A peer-reviewed history of U.S. medical compounding describes the division: state boards remain primary overseers of traditional pharmacy practice, while federal law sets conditions for the 503A exemptions.
"Bulk drug substance" sounds like a large batch. Here, bulk means the source ingredient used to make the preparation: the active chemical before a pharmacist turns it into a capsule, cream or sterile solution. The list answers whether a pharmacy may start with that ingredient under one part of Section 503A. It does not evaluate a finished formulation for a particular condition, set a dose or replace a patient-specific prescription.
Three routes can make a bulk ingredient eligible
FDA's current 503A overview, updated May 14, 2026, gives three alternatives. A bulk ingredient can meet the substance requirement if:
- it complies with an applicable USP or National Formulary monograph;
- if no such monograph exists, it is a component of an approved drug; or
- if neither condition applies, it appears on the 503A bulks list established by regulation.
Those are routes through the ingredient requirement, not a complete permission slip. The substance must also come with a valid certificate of analysis and be made by an establishment registered with FDA under Section 510. The pharmacy, prescription and preparation must satisfy the rest of Section 503A and applicable state law. Our guide to how compounded medications are made follows those handoffs from prescription to dispensing.
Category 1, 2 and 3 are interim policy buckets
Before FDA can put a substance into regulation, someone generally nominates it with supporting information. FDA reviews the nomination, consults the United States Pharmacopeia as appropriate and presents candidates to the Pharmacy Compounding Advisory Committee. The familiar category numbers came from an interim enforcement policy while that longer process continued. They are not three sections of the final list.
| Status | What it means | What a 503A pharmacy may do |
|---|---|---|
| Category 1 | The nomination supplied enough information for evaluation, the substance may be eligible and FDA had not identified a significant safety risk at categorization | FDA generally does not intend to act solely over the bulks-list requirement when the pharmacy follows the conditions in its interim-policy guidance; the ingredient is not yet on the final list |
| Category 2 | The nomination supplied enough information, but FDA identified significant safety risks | It is outside Category 1 enforcement discretion; FDA says it would consider regulatory action against compounding with it |
| Category 3 | The nomination lacked enough supporting information for evaluation | It is outside Category 1 enforcement discretion; FDA says it would consider regulatory action against compounding with it |
| On the 503A bulks list | FDA completed notice-and-comment rulemaking and codified the substance, sometimes with use restrictions | A pharmacy may use it through the list route, provided every other 503A condition is met |
The categories are also a snapshot, not a permanent queue. FDA says substances newly nominated after January 2025 are no longer put into Categories 1, 2 or 3 while the agency evaluates them. That is one reason "Category 1 list" and "503A bulks list" should not be used as synonyms.
An advisory vote is one step, not the last step
The Pharmacy Compounding Advisory Committee reviews FDA's evidence and makes a recommendation. FDA can accept or reject that advice. To change the legal list, the agency must publish a proposed rule, accept public comment and then publish a final rule. The committee vote is therefore meaningful, but nonbinding.
The 2019 final rule established the current six substances: Brilliant Blue G, cantharidin for topical use, diphenylcyclopropenone for topical use, N-acetyl-D-glucosamine for topical use, squaric acid dibutyl ester for topical use and thymol iodide for topical use. As of September 9, 2026, the day this article was written, FDA had published no decision or proposed rule adding BPC-157 after the July vote, and its meeting page carried no post-meeting minutes or summary; the codified list remained those six substances.
That small list is a useful reality check. Hundreds of nominations and an advisory discussion are not the same thing as a final regulatory amendment.
Where BPC-157 and TB-500 fit
At its July 23, 2026 meeting, the committee considered BPC-157 free base and BPC-157 acetate for ulcerative colitis. Promise's meeting analysis reported an 8–6 vote with one abstention to recommend adding both forms, against FDA review staff's recommendation. The FDA meeting page confirms the date, substances and indication; FDA's posted materials did not provide the tally. Our full account of the seven peptide votes keeps the meeting detail in one place.
The vote did not move BPC-157 onto the codified list. FDA's May 14, 2026 category document does not include it in Category 1, 2 or 3, and FDA's safety-risk page places it under "bulk drug substances nominated but withdrawn." FDA nevertheless evaluated the two forms on its own initiative. Its May 11, 2026 briefing document says neither has a USP/NF monograph and neither is a component of an approved drug.
TB-500 free base and acetate were considered for wound healing at the same meeting. They occupy their own record and do not inherit BPC-157's vote or evidence.
What the list does and does not tell a patient
The list governs the pharmacy's bulk-ingredient route. It does not tell you that a preparation has been demonstrated safe and effective for your goal. Being listed does not make an ingredient FDA-approved. In fact, this particular route exists for substances without a monograph that are not components of approved drugs. Compounded preparations do not go through FDA's premarket review of a finished product.
It also does not make the clinical decision. A licensed provider may still prescribe it; that decision is between you and your doctor. Whether a pharmacy may legally fill a particular prescription from a particular bulk ingredient is a separate question, governed by the ingredient's status and every other applicable rule. At Promise, a licensed provider reviews every request and not everyone qualifies.
Evidence remains another separate question. A 2025 HSS Journal systematic review scoped to orthopaedic sports medicine included 36 BPC-157 studies: 35 preclinical and one clinical, with no clinical safety data identified. That does not answer FDA's ulcerative-colitis question, and it does not turn a compounding vote into an efficacy result. The focused guide to BPC-157 side effects explains the human-data gap without stretching animal findings.
The exact chemical form matters, too. The committee considered BPC-157 free base and acetate separately but voted the same way on both; that does not create a blanket answer for anything sold under the peptide's name. A prescription and pharmacy record should identify the substance and formulation precisely enough that you know what was ordered and dispensed.
503B has a different list
Section 503B created a separate framework for registered outsourcing facilities, which may compound without first receiving patient-specific prescriptions but must follow federal current good manufacturing practice and other 503B conditions. Its bulks list is separate. A substance's position in the 503A process does not automatically carry over to 503B. The practical differences in prescription model, oversight and sourcing are laid out in our peptide compounding pharmacy guide.
For any compounded prescription, ask for the exact ingredient and form, the dispensing pharmacy's legal name, its state license, what appears on the label and whom to contact about a quality concern. Those facts tell you more than a seller saying only that a peptide is "under FDA review."
Where this analysis was published
Promise distributed the shorter analysis through FinanceWire on September 8, 2026. Markets Insider carried the release under the headline "Promise Launches Clinician-Guided BPC-157 Evaluation as FDA Panel Backs 503A Bulks List Addition". This article expands the list mechanics, interim categories and limits of the committee vote.